https://scholars.lib.ntu.edu.tw/handle/123456789/469804
標題: | A retrospective study of statin use and its effectiveness in Taiwanese | 作者: | Hsuan C.-F. Lee T.-L. Chang H.-L. Tseng W.-K. CHAU-CHUNG WU |
關鍵字: | Coronary heart disease; Lipid lowering; Statin | 公開日期: | 2009 | 卷: | 25 | 期: | 1 | 起(迄)頁: | 18-25 | 來源出版物: | Acta Cardiologica Sinica | 摘要: | Background: Epidemiological and clinical studies have clearly established the link between low-density lipoprotein cholesterol (LDL-C) and atherosclerosis-related cardiovascular consequences. All treatment guidelines developed in different countries identify LDL-C as a causative factor for cardiovascular disease and as a target for lipid-lowering therapy. Although it has been a common practice for physicians to prescribe statins for patients with dyslipidemia, there is little data regarding the effectiveness of statin therapy in Taiwanese. At the same time, the pattern of statin prescription by Taiwanese physicians has been obscure. Methods: We conducted a retrospective study of dyslipidemic Taiwanese patients receiving statin treatment between Sep. 2002 and Dec. 2004. Clinical information and laboratory parameters were collected by reviewing the medical records. The objective was to evaluate the performance of lipid-lowering therapies with statins. Results: A total of 961 dyslipidemic patients receiving steady dose of statins were selected from 6468 patients. The most commonly prescribed statin was simvastatin (31.8%, n = 306), and the most commonly used doses of different statins were medium potency such as atorvastatin 10 mg (93.4%), fluvastatin 80 mg (96.7%), lovostatin 20 mg (96.7%), pravastatin 10 mg (84.1%) and simvastatin 20 mg (84.3%). Among the five statins examined, atorvastatin appeared to be the most effective in terms of lowering LDL-C levels across all CHD risk groups. The proportion of attainment of guideline treatment goal was inversely related to cardiovascular risk, with less likelihood in the high cardiovascular group. Only 13.5% and 31% of high-risk patients attained the treatment goals for total cholesterol and LDL-C level, respectively. Conclusion: From this retrospective review, we conclude that despite the proven efficacy of statin in lipid-lowering therapy, there are still many patients not achieving their recommended LDL-C target levels. The percentage of successful lipid-lowering is lowest among the patients with highest risk (those with established cardiovascular disease or diabetes patients). There exists a big discrepancy between physicians' perception and the true rate of successful lipid control in Taiwan. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-66449083312&partnerID=40&md5=e6624985d6b8295535abde4db0d0f1c5 https://scholars.lib.ntu.edu.tw/handle/123456789/469804 |
ISSN: | 1011-6842 | SDG/關鍵字: | atorvastatin; cholesterol; fluindostatin; high density lipoprotein cholesterol; low density lipoprotein cholesterol; mevinolin; pravastatin; simvastatin; triacylglycerol; adult; allergic reaction; aminotransferase blood level; article; cardiovascular disease; cardiovascular risk; cholesterol blood level; controlled study; creatine kinase blood level; creatinine blood level; diabetic patient; drug efficacy; drug use; dyslipidemia; female; high risk population; human; ischemic heart disease; laboratory test; major clinical study; male; medical information; medical record review; myalgia; practice guideline; prescription; retrospective study; side effect; Taiwan; time series analysis |
顯示於: | 醫學教育暨生醫倫理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。